Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.52 +1.7%	$0.48	$0.40 ▼ $6.84	$27.50M	1.11	752,919 shs	360,088 shs
CVKD Cadrenal Therapeutics	$11.35 +0.5%	$13.39	$5.70 ▼ $22.90	$22.36M	0.95	33,584 shs	7,441 shs
KA Kineta		$0.66	$0.33 ▼ $5.39	$7.04M	0.46	409,478 shs	530,700 shs
KALA KALA BIO	$5.81 +1.1%	$4.51	$2.92 ▼ $11.20	$37.44M	-1.88	49,983 shs	27,323 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	+4.99%	+4.67%	-10.53%	-91.76%
CVKD Cadrenal Therapeutics	0.00%	-12.62%	-8.58%	-30.22%	+1,128,999,900.00%
KA Kineta	0.00%	0.00%	0.00%	0.00%	-16.25%
KALA KALA BIO	0.00%	-1.88%	+42.08%	+74.47%	-15.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.3074 of 5 stars	3.4	3.0	0.0	0.0	1.1	4.2	1.3
CVKD Cadrenal Therapeutics	2.202 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.6
KA Kineta	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	3.6106 of 5 stars	3.5	2.0	0.0	4.4	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.71	Moderate Buy	$3.30	540.78% Upside
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	181.94% Upside
KA Kineta	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.00	123.94% Upside

Current Analyst Ratings Breakdown

Latest KA, KALA, ALXO, and CVKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/16/2025	CVKD Cadrenal Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$4.17 per share	N/A
KA Kineta	$5.44M	0.00	N/A	N/A	$0.29 per share	0.00
KALA KALA BIO	$3.89M	9.63	N/A	N/A	$2.02 per share	2.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	8/14/2025 (Estimated)
CVKD Cadrenal Therapeutics	-$10.65M	-$9.26	N/A	N/A	N/A	N/A	-244.94%	-181.94%	8/6/2025 (Estimated)
KA Kineta	-$14.10M	-$1.50	N/A	N/A	N/A	N/A	-1,044.95%	-336.46%	N/A
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)

Latest KA, KALA, ALXO, and CVKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALXO ALX Oncology	-$0.46	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A
5/8/2025	Q1 2025	CVKD Cadrenal Therapeutics	-$1.64	-$2.09	-$0.45	-$2.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
KA Kineta	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.09	5.47	5.47
CVKD Cadrenal Therapeutics	N/A	4.32	4.32
KA Kineta	0.05	0.14	0.14
KALA KALA BIO	3.19	1.99	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
CVKD Cadrenal Therapeutics	7.92%
KA Kineta	30.32%
KALA KALA BIO	24.61%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
CVKD Cadrenal Therapeutics	48.62%
KA Kineta	23.70%
KALA KALA BIO	8.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
CVKD Cadrenal Therapeutics	4	1.97 million	1.01 million	Not Optionable
KA Kineta	40	12.25 million	9.35 million	Not Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable

KA, KALA, ALXO, and CVKD Headlines

Recent News About These Companies

LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA)

July 14, 2025 | americanbankingnews.com

KALA BIO (NASDAQ:KALA) Raised to "Hold" at Wall Street Zen

July 14, 2025 | americanbankingnews.com

KALA Bio completes enrollment of CHASE clinical trial

July 12, 2025 | ophthalmologytimes.comO

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial ...

July 11, 2025 | morningstar.comM

KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial ... - Nasdaq

July 11, 2025 | nasdaq.com

KALA BIO Inc. (KALA) Stock Price Today - WSJ - The Wall Street Journal

July 10, 2025 | wsj.com

KALA BIO, Inc.: KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 9, 2025 | finanznachrichten.de

Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial

July 9, 2025 | tipranks.com

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

July 9, 2025 | globenewswire.com

Kala Bio Inc Valuation - Morningstar

July 8, 2025 | morningstar.comM

KALA BIO, Inc. (KALA) - Yahoo Finance

July 1, 2025 | finance.yahoo.com

KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in Stock

June 27, 2025 | insidertrades.com

Mary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

June 5, 2025 | insidertrades.com

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | finance.yahoo.com

Chief Minister cancels programme over unauthorised nature of venue

April 20, 2025 | thehindu.com

KALA BIO: Q4 Earnings Snapshot

March 31, 2025 | timesunion.comT

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | markets.businessinsider.com

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

February 26, 2025 | finance.yahoo.com

Kala Bio announces CEO departure, appoints interim leader

February 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KA, KALA, ALXO, and CVKD Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.52 +0.01 (+1.66%)

As of 12:00 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Cadrenal Therapeutics NASDAQ:CVKD

$11.35 +0.06 (+0.53%)

As of 12:00 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Kineta NASDAQ:KA

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

KALA BIO NASDAQ:KALA

$5.80 +0.07 (+1.13%)

As of 11:58 AM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time